Barry Canton serves as Executive at Ginkgo Bioworks Holdings, Inc., where they oversee executive responsibilities. Since joining the company, Barry Canton has executed 258 insider transactions totaling $59.8M, demonstrating a bearish approach to their equity position. Their most recent transaction on Oct 3, 2022 involved selling 343,072 shares valued at $1.1M.
Barry Canton currently holds 12,374,544 shares of Ginkgo Bioworks Holdings, Inc. (DNA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Barry Canton has been a net seller of DNA stock. They have purchased $0 and sold $59.8M worth of shares.
Barry Canton's most recent insider trade was on Oct 3, 2022, when they sold 343,072 shares at $3.12 per share.
Get notified when new Form 4 filings are submitted
| $3.12 |
| Discretionary |
| Sep 30, 2022 | DNA | $0 | Option Exercise | 773,453 | $N/A | Discretionary |
| Sep 30, 2022 | DNA | $0 | Option Exercise | 773,453 | $N/A | Discretionary |
| Dec 7, 2021 | DNA | $0 | Gift | 200,000 | $N/A | Discretionary |
| Dec 6, 2021 | DNA | $0 | Conversion | 200,000 | $N/A | Discretionary |
| Oct 1, 2021 | DNA | $0 | Option Exercise | 25,782,354 | $N/A | Discretionary |
| Oct 1, 2021 | DNA | $0 | Option Exercise | 25,782,354 | $N/A | Discretionary |